Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2022

Open Access 01-12-2022 | Escherichia Coli | Case report

Heparin-induced thrombocytopenia following Shiga-toxin-associated hemolytic uremic syndrome: a case report

Authors: Elia Rigamonti, Tecla Bonora, Mariangela Ventresca, Pietro Cippà

Published in: Journal of Medical Case Reports | Issue 1/2022

Login to get access

Abstract

Background

Up to 50% of cases of Shiga-toxin-producing Escherichia coli hemolytic uremic syndrome occur in adults, and the clinical presentation is variable. Microbiological analyses must be performed in all patients with thrombotic microangiopathy to identify Shiga-toxin-producing Escherichia coli, even in the absence of diarrhea.

Case presentation

A 79-year-old Caucasian woman was admitted to hospital because of severe proctitis. In the following days, the patient’s level of consciousness declined, and she developed acute kidney injury, thrombocytopenia, and hemolytic anemia. Shiga-toxin-producing Escherichia coli was found in fecal cultures, suggesting the diagnosis of hemolytic uremic syndrome. In the following days, her clinical conditions improved, but thrombocytopenia worsened, and the patient developed posterior tibial vein thrombosis. The discordant evolution of thrombocytopenia compared with other clinical and laboratory parameters prompted a new evaluation of its causes. Diagnosis of heparin-induced thrombocytopenia was confirmed by heparin-induced platelet aggregation assay and positive antibodies to platelet factor 4.

Conclusions

A discordant evolution of platelet count in patients with thrombotic microangiopathy requires a systematic reevaluation of the thrombocytopenia.
Literature
1.
go back to reference George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371:654.CrossRef George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371:654.CrossRef
2.
go back to reference Tarr PI, Gordon CA, Chandler WL. Shiga-toxin producing Escherichia coli and hemolytic uremic syndrome. Lancet. 2005;365(9464):1073–86.PubMed Tarr PI, Gordon CA, Chandler WL. Shiga-toxin producing Escherichia coli and hemolytic uremic syndrome. Lancet. 2005;365(9464):1073–86.PubMed
3.
go back to reference Bielaszewska M, Karch H. Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium. Thromb Haemost. 2005;94:312–8.PubMed Bielaszewska M, Karch H. Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium. Thromb Haemost. 2005;94:312–8.PubMed
4.
go back to reference Studt JD, Binet I, Nair G, et al. Heparin-induced thrombocytopenia associated with thrombotic microangiopathy. Hamostaseologie. 2013;33:160–3.CrossRef Studt JD, Binet I, Nair G, et al. Heparin-induced thrombocytopenia associated with thrombotic microangiopathy. Hamostaseologie. 2013;33:160–3.CrossRef
5.
go back to reference Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2003;121:535–55. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2003;121:535–55.
6.
go back to reference Kremer Hovinga JA, Meyer SC. Current management of thrombotic thrombocytopenic purpura. Curr Opin Hematol. 2008;15:445–50.CrossRef Kremer Hovinga JA, Meyer SC. Current management of thrombotic thrombocytopenic purpura. Curr Opin Hematol. 2008;15:445–50.CrossRef
7.
go back to reference Keenswijk W, Raes A, De Clerck M, et al. Is plasma exchange efficacious in Shiga toxin-associated hemolytic uremic syndrome ? A narrative review of current evidence. Ther Apher Dial. 2019;23:118–25.CrossRef Keenswijk W, Raes A, De Clerck M, et al. Is plasma exchange efficacious in Shiga toxin-associated hemolytic uremic syndrome ? A narrative review of current evidence. Ther Apher Dial. 2019;23:118–25.CrossRef
9.
go back to reference Alberio LA, Angelillo-Scherrer A, Asmis LM, et al. Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland. Swis Med Wkly. 2020;150:w20210. Alberio LA, Angelillo-Scherrer A, Asmis LM, et al. Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland. Swis Med Wkly. 2020;150:w20210.
10.
go back to reference Bruyand M, Mariani-Kurkdjian P, Gouali M, et al. Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection. Med Mal Infect. 2018;48:167–74.CrossRef Bruyand M, Mariani-Kurkdjian P, Gouali M, et al. Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection. Med Mal Infect. 2018;48:167–74.CrossRef
11.
go back to reference Khalid M, Andreoli S. Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli. Pediatr Nephrol. 2019;34:2495–507.CrossRef Khalid M, Andreoli S. Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli. Pediatr Nephrol. 2019;34:2495–507.CrossRef
14.
go back to reference Poolpol K, Orth-Höller D, Speth C, et al. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. Mol Immunol. 2014;58(1):77–84.CrossRef Poolpol K, Orth-Höller D, Speth C, et al. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. Mol Immunol. 2014;58(1):77–84.CrossRef
15.
go back to reference Morigi M, Galbusera M, Gastoldi S, et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol. 2011;187(1):172–80.CrossRef Morigi M, Galbusera M, Gastoldi S, et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol. 2011;187(1):172–80.CrossRef
Metadata
Title
Heparin-induced thrombocytopenia following Shiga-toxin-associated hemolytic uremic syndrome: a case report
Authors
Elia Rigamonti
Tecla Bonora
Mariangela Ventresca
Pietro Cippà
Publication date
01-12-2022

Other articles of this Issue 1/2022

Journal of Medical Case Reports 1/2022 Go to the issue